Keenova Reports Q3 2026 Financial Results
Third-quarter net sales from continuing operations reached $550 million. The results supported updated guidance for Acthar Gel and XIAFLEX growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed